Thromboembolic and haemorrhagic complications in patients treated with anticoagulants after artificial heart valve replacement. Risks factors dependent on quality of anticoagulant treatment;Powikłania zakrzepowo-zatorowe i krwotoczne u pacjentów po wszczepieniu sztucznej zastawki serca leczonych doustnymi lekami przeciwzakrzepowymi. Czynniki ryzyka zależne od jakości leczenia przeciwzakrzepowego

Polskie Archiwum Medycyny Wewnetrznej

Volumn 114, Issue 1, 2005, Pages 673-680

  Wołkanin Bartnik, Jolanta ^a   Zieliński, Tomasz ^b   Pogorzelska, Hanna ^a   Browarek, Aldona ^b   Leszek, Przemysław ^b   Korewicki, Jerzy ^b  

^a Klinika I Zak ad Rehabilitacji Kardiologicznej I Elektrokardiologii Nieinwazyjnej

^b INSTITUTE OF CARDIOLOGY   (Poland)

Author keywords

International normalized ratio (INR); Mechanical heart valves; Oral anticoagulant; Thromboembolic and haemorrhagic complications

Indexed keywords

ANTICOAGULANT AGENT;

ADULT; AGED; ARTICLE; BLEEDING; CONTROLLED STUDY; FOLLOW UP; HEALTH CARE QUALITY; HEART VALVE PROSTHESIS; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MORBIDITY; MORTALITY; RISK FACTOR; THROMBOEMBOLISM; FEMALE; HEART VALVE REPLACEMENT; MALE; MIDDLE AGED; POLAND; STATISTICAL MODEL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; FEMALE; FOLLOW-UP STUDIES; HEART VALVE PROSTHESIS; HEART VALVE PROSTHESIS IMPLANTATION; HEMORRHAGE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; POLAND; RISK FACTORS; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 33646457447     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Horstkotte D., Schulte H., Bircs W., Strauer B.: Unexpected findings concerning thromboembolic complications and anticoagulation after complete 10 years follow up of patients with St. Jude Medical prosteses. J. Heart Valve Dis. 1993, 3, 2.
2. Kvidal P., Bergstrom R., Malm T., Stahle E.: Long-term follow-up of morbidity and mortality after aortic valve replacement with a mechanical valve prothesis. Eur. Heart J. 2000, 21, 1099.
3. Saour J.N., Sieck J.O., Mamo L.A.:Trial of different intensities of anticoagulation in patients with prosthetic heart valves. N. Engl. J. Med., 1990, 322, 428.
4. Horstkotte D. Scharf R.E., Schultheiss H.P.: Intracardiac thrombosis: patient-related and device-related factors J. Heart Valve Dis. 1995, 4, 114.
5. Butchart E.G.: Thrombogenesis and anticoagulation in heart valve disease: towards a rational approach. J. Heart Valve Dis. 1993, 2, 1.
6. Horstkotte D., Hering D., Faber L.: Cardiac morphology and physiology predisposing to thrombus formation. Eur. Haert J. (suppl.) 2001, 3, 11.
7. Rasche H.: Haemostasis and thrombosis: an overview. Eur. Heart J. (suppl.) 2001, 3, 3.
8. Akins C.: Mechanical cardiac valvular prosteses. Ann. Thorac Surg., 1991, 52, 16172.
9. Cannegieter S.C., Torn M., Rosendaal F.R.: Oral anticoagulant treatment in patients with mechanical heart valves: how to reduce the risk of thromboembolic and bleeding complications. J. Int. Med., 1999, 245, 369.
10. Butchrt E.G.: Rationalizing antithrombotic management for patients with prosthetic heart valves J. Heart Valve Dis. 1995, 4, 106.
11. Dalen J., Hirsh J.: The Sixth (2000) ACCP guidelines for antithrombotic therapy for prevention and treatment of thrombosis chest, 2001, 119 (suppl.).
12. Taborski U., Muller-Berghaus G.: State-of-art patient self-management for control of oral anticoagulation. Seminars in thrombosis and haemostasis 1999, 25.
13. Muller E., Bergmann R. and the GELIA study group: Economic analysis of bleeding and throboembolic sequele after heart valve replacement (GELIA 7). Eur. Heart J. (suppl.) 2001, 3, 65.
14. Van den Besselaar A.: International standarization of laboratory control of oral anticoagulant therapy: a survey of thromboplastin reagents used for prothrombin time testing. J. Heart. Valve Dis. 1993, 42.
15. Szczepański M.: Doustne antykoagulanty. Post. Nauk Med. IX, 160-167.
16. "Zatory i zakrzepy" pod red. Stanisława Łopaciuka. PZWL, Warszawa, 1996.
17. Hirsh J.: Oral anticoagulant drags. N. Eng. J. Med., 1991, 324, 1865.
18. Hirsh J., Dalen J.E., Deykin D.: Oral anticoagulants. Mechanism of action, clinical effectivness, and optimal therapeutic range. Chest 1992, 102, 312.
19. Horstkotte D.: Optimal frequency of patient monitoring and intensity of oral anticoagulation therapy in valvular heart disease. J. Thromb. Thrombolysis, 1998, 5, 19.